Recently, GenSci announced that the marketing application of its Leuprorelin Injection Emulsion ( Camcevi ) has been accepted by the National Medical Products Administration ( NMPA ), and it is intended for Androgen Deprivation Therapy ( ADT ) of advanced prostate cancer.

Leuprorelin Injection Emulsion  is a gonadotropin-releasing hormone ( GnRH ) agonist. Administered subcutaneously, it forms a solid implant that gradually releases Leuprolide over six months with just one shot. The product can significantly enhance patient compliance through its extended dosing interval.

This product is developed through the collaboration of Accord BioPharma and GenSci, and we holds the rights in the Chinese market. It has already received approval in the United States, Canada, EU, and Taiwan region of China for prostate cancer treatment. The current application for market approval will significantly enhance the convenience of using  Leuprorelin Injection Emulsion  for patients with advanced prostate cancer.